In addition to administering the fifth National Treatment Survey in 2018, IDF also asked participants to complete, where appropriate, the Ig Patient Experience with Treatment (IgPET) Scale, the Treatment Satisfaction Questionnaire for Medication (TSQM-9), SF-12 and SF-10. The National Treatment Experiences and Preferences Survey data provides clinicians, researchers, and, most importantly, patients and their families with the only national estimates of treatment experiences of patients with primary immunodeficiencies.
